Bronchogen

What Bronchogen is, structurally

Bronchogen is a tetrapeptide with a free N-terminal amine and a free C-terminal acid.

The formula reconciles with the sequence exactly. Four nitrogens means four backbone amides and no side-chain nitrogen, ruling out lysine, arginine, histidine, asparagine and glutamine. The nine oxygens divide as five on the backbone, two of them the terminal acid, and four across the acidic side chains.

Charge sits firmly negative. Aspartate and glutamate each carry a carboxylate and the C-terminus carries a third, against a single N-terminal amine. Nothing in the sequence is basic.

The leucine distinguishes this peptide's physical behaviour. Its isobutyl side chain is the only hydrophobic group present, and in a chain of four residues that is a substantial fraction of the whole, giving the peptide a modest non-polar surface where the acidic residues give it none. It stays water soluble and clearly polar, but it is not the uniformly hydrophilic material an all-acidic sequence would be. No quantitative solubility figure is quoted here.

There is no cysteine, so no thiol and no disulfide chemistry, no methionine, and no proline to constrain the backbone. There is also no aromatic residue anywhere, which determines how purity is measured.

Reconstitution and handling

Sterile water is the default solvent. No metal centre is present, so PBS or an appropriate assay buffer are equally suitable. Add diluent down the vial wall, swirl gently, and let the solution clarify. Vortexing only adds foaming.

Adsorption onto plasticware is worth allowing for at low concentration, and low-protein-binding tubes reduce measured loss. The leucine gives this peptide slightly more affinity for polypropylene than a purely acidic sequence would have.

This is laboratory preparation chemistry, not dosing, administration, or protocol guidance of any kind.

Storage and stability

Store the lyophilized powder at -20 degrees C, sealed, desiccated and protected from light, and let a cold vial warm before opening. Reconstituted, hold at 2 to 8 degrees C, or aliquot and freeze rather than thawing repeatedly.

The degradation profile is narrow because of what the sequence lacks. No cysteine means no thiol oxidation, no methionine means no sulfoxide, and no asparagine or glutamine means no deamidation. Oxidation is not a concern.

The liability that does exist is the aspartate at position three. Aspartyl residues cyclise to a succinimide intermediate and reopen as isoaspartate, rearranging the backbone while the mass stays identical. Mild acid and warmth drive it. Here the aspartate is followed by leucine rather than by glycine, which is the fastest-rearranging neighbour, so this is not the worst case for the motif, but cold and near-neutral storage remains the right handling.

These are storage conditions for the material, not dosing or administration guidance.

How Bronchogen is tested

Reversed-phase HPLC establishes chromatographic purity as area percent. There is no tryptophan, tyrosine or phenylalanine in this sequence, so nothing absorbs at 280 nm and detection has to sit near 214 nm where the amide bond absorbs.

Retention is where this compound differs from shorter, purely acidic peptides. The leucine gives a C18 stationary phase something to hold, so it elutes as a defined peak rather than near the void volume, which makes separation from close impurities more straightforward.

Area percent is a chromatographic measure and not peptide content by weight. Solid-phase synthesis delivers a salt, usually trifluoroacetate or acetate, and that counter-ion is outside the molecular weight above, so the vial does not contain only peptide. Residual trifluoroacetate and deletion sequences are the classes to resolve, and on a four-residue chain a single deletion is a large proportional mass change.

Mass spectrometry confirms identity against the expected weight. It cannot detect the isoaspartate rearrangement, which is isobaric, so that has to be caught chromatographically.

Intact mass has a second blind spot on this particular sequence. The same four residues ordered Ala-Asp-Glu-Leu give an identical formula and an identical weight, because aspartate and glutamate differ by exactly one CH2 and transposing them relocates that CH2 without changing the total. Part of the published literature uses that ordering, so the distinction is not hypothetical. Tandem MS separates the two outright: fragmenting the chain yields a b2 ion near 201 for Ala-Glu against 187 for Ala-Asp, a 14-unit difference that reads directly on which residue occupies position two. Intact-mass methods, including MS-UPLC, cannot make that call.

These describe general methodology, not a claim about any particular batch.

Handling FAQ

Why measure purity at 214 nm rather than 280 nm? Because none of the four residues is aromatic. Tryptophan, tyrosine and phenylalanine are what give a peptide absorbance near 280 nm, and this sequence has none of them. The amide bond absorbs in the low UV instead.

Does the leucine change how it behaves in solution? Modestly, and mostly on a column. It is the only hydrophobic group in a very short chain, so it gives measurable reversed-phase retention that an all-acidic sequence would lack. It does not make the peptide poorly water soluble.

Full specifications for Bronchogen.